Interaction Checker
Potential Interaction
Lopinavir/ritonavir (LPV/r)
Tenofovir-DF (TDF)
Quality of Evidence: Low
Summary:
Coadministration of tenofovir-DF (300 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) had no significant effect on lopinavir/ritonavir PK parameters; tenofovir AUC increased by 32%, Cmin increased by 51%, and there was no change in Cmax. A higher risk of renal impairment has been reported in patients receiving tenofovir-DF and a ritonavir boosted protease inhibitor. No dose adjustment is recommended, but close monitoring of renal function and for tenofovir-associated adverse reactions is required.
Description:
Coadministration of Kaletra and tenofovir (300 mg once daily) increased tenofovir AUC and Cmin by 32% and 51% respectively, but had no effect on Cmax. Higher tenofovir concentrations could potentiate tenofovir associated adverse events, including renal disorders. No dose adjustment necessary.
Kaletra Summary of Product Characteristics, AbbVie Ltd, January 2021.
Coadministration of tenofovir (300 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) to 24 HIV- volunteers resulted in no change in tenofovir Cmax, but increases of 32% and 51% in tenofovir AUC and Cmin respectively. Patients receiving Kaletra and tenofovir should be monitored for adverse reactions associated with tenofovir.
Kaletra Prescribing Information, AbbVie Ltd, October 2020.
When tenofovir disoproxil fumarate (300 mg once daily) was administered with lopinavir/ritonavir (400/100 mg twice daily), there was no significant effect on lopinavir/ritonavir PK parameters. Tenofovir AUC increased by 32%, Cmin increased by 51%, and there was no change in Cmax. No dose adjustment is recommended. The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders. A higher risk of renal impairment has been reported in patients receiving tenofovir disoproxil fumarate in combination with a ritonavir or cobicistat boosted protease inhibitor. A close monitoring of renal function is required in these patients. In patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
Viread Summary of Product Characteristics, Gilead Sciences Ltd, September 2016.
Coadministration of lopinavir/ritonavir (400/100 mg twice times daily for 14 days) and tenofovir-DF (300 mg once daily) was investigated in 24 healthy volunteers. There was no change in tenofovir Cmax; AUC and Cmin increased by 32% and 51% respectively. There was no change in Cmax, AUC or Cmin for lopinavir or ritonavir. Patients receiving tenofovir-DF concomitantly with lopinavir/ritonavir should be monitored for tenofovir-associated adverse reactions. Tenofovir-DF should be discontinued in patients who develop tenofovir-associated adverse reactions.
Viread Prescribing Information, Gilead Sciences Inc, February 2016.
Plasma concentrations of tenofovir (300 mg once daily) with lopinavir/ritonavir (400/100 mg twice daily, n=14) or nevirapine (400 mg once daily, n=13) were determined in HIV positive patients. Tenofovir AUC, Cmax and Ctrough were 50%, 33% and 72% higher, respectively, in the presence of lopinavir/ritonavir when compared to nevirapine. The authors suggest that observed increase in tenofovir exposure may involve intestinal P-gp inhibition by lopinavir and/or ritonavir.
Pilot pharmacokinetic study of Human Immunodeficiency Virus-infected patients receiving tenofovir disoproxil fumarate (TDF): Investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Pruvost A, Negredo E, Théodoro F, et al. Antimicrob Agents Chemother, 2009, 53(5): 1937-1943.
The pharmacokinetic interaction between tenofovir (300 mg once daily) and lopinavir (400/100 mg twice daily) was determined in 27 HIV-negative subjects. Coadministration of lopinavir/ritonavir increase tenofovir AUC (32%), Cmax (15%) and Cmin (51%). Lopinavir and ritonavir pharmacokinetics were unaffected by tenofovir (n=24). Clinical estimates of renal function were unaffected by administration of tenofovir alone or with lopinavir/ritonavir. The increase in tenofovir exposure is not believed to be clinically relevant based on the safety and efficacy of this combination in HIV-infected patients in long-term controlled clinical trials.
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. Kearney BP, Mathias A, Mittan A, et al. J Acquir Immune Defic Syndr, 2006, 43: 278-283.
The effect of lopinavir/ritonavir (400/100 mg twice daily) on the renal clearance of tenofovir was investigated in HIV-infected subjects receiving tenofovir (300 mg once daily) alone or in combination with LPV/r. Tenofovir clearance was 16% lower in subjects receiving LPV/r, consistent with a renal interaction between tenofovir and LPV/r. There was no difference in tenofovir-diphosphate concentrations when tenofovir was given alone or in combination.
Effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Kiser J, et al. 13th Conference on Opportunistic Infections and Retroviruses, Denver, February 2006, abstract 570.
Significant increases in TDF plasma exposure have been reported when coadministered with Kaletra. This study looked at the interaction at the intracellular level by investigating the effect of LPV/RTV (400/100 once daily) on TDF-DP concentrations in HIV+ patients taking TDF (300 mg once daily). There was a trend to higher TDF-DP concentrations when used in combination with LPV/r. However, due to interpatient variability, this did not reach statistical significance. Mean ± SD TDF-DP concentrations were 181.4 ± 80.1 and 280.3 ± 181.8 fmol/106 cells, alone and in combination with LPV/RTV respectively. Since target concentrations have yet to be defined for TDF-DP, the possible consequences of this increase remain unknown.
Possible interaction between tenofovir and boosted lopinavir; analysis at the intracellular level in HIV infected patients. Benech, H et al. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, April 2005, abstract 34.
The effect of tenofovir on the pharmacokinetics of lopinavir and ritonavir was investigated in 18 treatment experienced HIV+ patients. Lopinavir concentrations decreased in the presence of tenofovir (Cmin from 4.61 to 3.06 µg/ml; Cmax from 10.68 to 9.65 µg/ml). Decreases in ritonavir concentrations were also observed (Cmin from 0.63 to 0.35 µg/ml; Cmax from 1.02 to 0.72 µg/ml). Therapeutic drug monitoring of lopinavir when coadministered with tenofovir may be useful to indicate if individual dose modification of lopinavir and/or ritonavir is required.
Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV+ patients. Breilh D, Rouzes A, Djabarouti S, et al. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, October/November 2004, abstract A-445.
Lopinavir trough concentrations were obtained from 14 HIV+ patients receiving lopinavir with tenofovir and from 15 patients without tenofovir. Lopinavir Ctroughs were 5.6 µg/ml in the tenofovir group and 7.0 µg/ml without tenofovir.
Comparison of lopinavir/r plasma levels with and without tenofovir as part of HAART in HIV-1 infected patients. Scarsi K, Postelnick M, Murphy R. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 26.
Potential Interaction
Ritonavir (RTV)
Tenofovir-DF (TDF)
Quality of Evidence: Low
Summary:
Coadministration with ritonavir alone has not been studied. Coadministration of tenofovir-DF and ritonavir (100 mg twice daily with lopinavir, darunavir or saquinavir) had no significant effect on ritonavir concentrations. However, a higher risk of renal impairment has been reported in patients receiving tenofovir-DF in combination with a ritonavir boosted protease inhibitor. Close monitoring of renal function is required in these patients.
Description:
When tenofovir disoproxil fumarate was administered with low dose ritonavir (as lopinavir/ritonavir), there was no significant effect on lopinavir/ritonavir PK parameters; tenofovir AUC and Cmin increased by 32% and 51%, but there was no change in Cmax. Coadministration as darunavir/ritonavir had no significant effect on darunavir/ritonavir PK parameters, but increased tenofovir AUC and Cmin by 22% and 37%. A higher risk of renal impairment has been reported in patients receiving tenofovir disoproxil fumarate in combination with a ritonavir or cobicistat boosted protease inhibitor. A close monitoring of renal function is required in these patients. In patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
Viread Summary of Product Characteristics, Gilead Sciences Ltd, September 2016.
Coadministration of low dose ritonavir (coformulated as lopinavir/ritonavir, 400/100 mg twice times daily for 14 days) and tenofovir-DF (300 mg once daily) was investigated in 24 healthy volunteers. There was no change in tenofovir Cmax; AUC and Cmin increased by 32% and 51% respectively. There was no change in Cmax, AUC or Cmin for lopinavir or ritonavir. When low dose ritonavir (100 mg twice daily for 14 days) was coadministered with saquinavir (1000 mg twice daily ) and tenofovir (300 mg once daily) in 35 healthy volunteers, there was no change in tenofovir AUC or Cmax, but Cmin increased by 23%. There was no change in ritonavir Cmax or AUC, but Cmin increased by 23%.
Viread Prescribing Information, Gilead Sciences Inc, February 2016.
The coadministration of tenofovir diproxil fumarate (300 mg once daily) was investigated in 18 HIV-1 infected individuals receiving saquinavir hard gel/ritonavir combination (1000/100 mg twice daily). On day 1, 12 h pharmacokinetic profiles for saquinavir and ritonavir were obtained, tenofovir was then added to the regimen and blood sampling repeated at days 3 and 14. Following the addition of tenofovir, saquinavir and ritonavir plasma concentrations were not significantly different compared with day 1. Geometric mean ratios (95% confidence intervals) for the AUC on days 3 and 14 were 1.16 (0.97, 1.59) and 0.99 (0.87, 1.30) for saquinavir and 1.05 (0.92, 1.28) and 1.08 (0.97, 1.30) for ritonavir.
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Boffito M, Back D, Stainsby-Tron M, et al. Br J Clin Pharmacol, 2005, 59: 38-42.
The effect of tenofovir on the pharmacokinetics of lopinavir and ritonavir was investigated in 18 treatment experienced HIV+ patients. Lopinavir concentrations decreased in the presence of tenofovir (Cmin from 4.61 to 3.06 µg/ml; Cmax from 10.68 to 9.65 µg/ml). Decreases in ritonavir concentrations were also observed (Cmin from 0.63 to 0.35 µg/ml; Cmax from 1.02 to 0.72 µg/ml). Therapeutic drug monitoring of lopinavir when coadministered with tenofovir may be useful to indicate if individual dose modification of lopinavir and/or ritonavir is required.
Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV+ patients. Breilh D, Rouzes A, Djabarouti S, et al. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, October/November 2004, abstract A-445.
Coadministration of hard gel saquinavir/ritonavir (1000/100 mg twice daily) alone and with tenofovir (300 mg once daily) was studied in 40 healthy subjects. The pharmacokinetics of tenofovir were not substantially effected by saquinavir/ritonavir (Cmin, Cmax and AUC increased by 23%, 15% and 14% respectively). Ritonavir exposure was slightly increased; Cmin, Cmax and AUC increased by 23%, 10% and 11% respectively. Saquinavir Cmin was moderately enhanced (47% increase); Cmax and AUC increased by 22% and 29% respectively. All subjects achieved a SQV Cmin above 100 ng/ml.
Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjects. Zong J, Chittick G, Blum MR, et al. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, October/November 2004, abstract A-444.
Coadministration of ritonavir (100 mg once daily, given with atazanavir) and tenofovir (300 mg once daily) was investigated in 10 male HIV+ subjects. In the presence of tenofovir, there were decreases in ritonavir AUC (7011 to 5217 ng/ml.h), Cmax (886 to 642 ng/ml) and Cmin (43 to 39 ng/ml). Atazanavir concentrations were also decreased in the presence of tenofovir.
Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV-infected patients with multiple treatment failures: a sub-study of PUZZLE2-ANRS 107 trial. Taburet AM, Piketty C, Gerard L, et al. 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003. Abstract 537.
Potential Interaction
Lopinavir/ritonavir (LPV/r)
Ritonavir (RTV)
Quality of Evidence: Low
Summary:
Coadministration of ritonavir (100 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) increased lopinavir Cmax (28%) and AUC (46%), and Cmin (116%). Appropriate doses of additional ritonavir in combination with lopinavir/ritonavir with respect to safety and efficacy have not been established.
Description:
LHPG Comment: Lopinavir is co-formulated with ritonavir. Additional ritonavir will increase exposure.
Lopinavir coformulated with ritonavir as a pharmacokinetic enhancer has been approved for use at the noted doses: lopinavir/ritonavir 400/100 mg or 800/200 mg.
Norvir Summary of Product Characteristics, AbbVie Ltd, September 2016.
Coadministration of ritonavir (100 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) to 8 HIV+ subjects increased lopinavir Cmax, AUC and Cmin by 28%, 46% and 116%, respectively (compared to data from 21 subjects receiving lopinavir/ritonavir 400/100 mg twice daily). Appropriate doses of additional ritonavir in combination with Kaletra with respect to safety and efficacy have not been established.
Kaletra Prescribing Information, AbbVie Inc, October 2020.
Potential Interaction
Tenofovir-DF (TDF)
Sofosbuvir/Velpatasvir
Quality of Evidence: Low
Summary:
Sofosbuvir/velpatasvir increased tenofovir AUC by ~30-80% when administered with various regimens containing tenofovir-DF. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed. The safety of increased tenofovir concentrations in these settings has not been established. Monitor for tenofovir-associated adverse reactions. The potential risks and benefits associated with coadministration should be considered, particularly in patients at increased risk of renal dysfunction. The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders and renal function should be closely monitored. If other alternatives are not available, patients receiving sofosbuvir/velpatasvir concomitantly with tenofovir-DF and a boosted HIV protease inhibitor should be monitored for adverse reactions related to tenofovir-DF. No dose adjustment is recommended for patients receiving sofosbuvir/velpatasvir concomitantly with tenofovir-DF and raltegravir or rilpivirine. Coadministration of sofosbuvir/velpatasvir and efavirenz containing regimens is not recommended as it is expected to decrease plasma concentrations of velpatasvir.
Description:
Epclusa has been shown to increase tenofovir exposure (P-gp-inhibition). The increase in tenofovir exposure (AUC and Cmax) was around 40-80% during co-treatment with Epclusa and tenofovir disoproxil fumarate/emtricitabine as part of various HIV regimens. Patients receiving tenofovir disoproxil fumarate and Epclusa concomitantly should be monitored for adverse reactions associated with tenofovir disoproxil fumarate. Refer to the tenofovir disoproxil fumarate-containing product’s Summary of Product Characteristics for recommendations on renal monitoring. Epclusa has been shown to increase tenofovir exposure, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat). The safety of tenofovir disoproxil fumarate in the setting of Epclusa and a pharmacokinetic enhancer has not been established. The potential risks and benefits associated with co-administration of Epclusa with the fixed-dose combination tablet containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or tenofovir disoproxil fumarate given in conjunction with a boosted HIV protease inhibitor (e.g. atazanavir or darunavir) should be considered, particularly in patients at increased risk of renal dysfunction. Patients receiving Epclusa concomitantly with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for tenofovir-associated adverse reactions. Refer to tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate Summary of Product Characteristics for recommendations on renal monitoring.
Epclusa Summary of Product Characteristics, Gilead Sciences Ltd, July 2016.
Coadministration may increase tenofovir concentrations. Monitor for tenofovir-associated adverse reactions in patients receiving Epclusa concomitantly with a regimen containing tenofovir DF. Refer to the prescribing information of the tenofovir DF-containing product for recommendations on renal monitoring.
Coadministration of tenofovir-DF (300 mg once daily with emtricitabine, atazanavir and ritonavir) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 24 subjects. Cmax and AUC of sofosbuvir increased by 12% and 22%; Cmax, AUC and Cmin of GS-331007 increased by 21%, 32% and 42% respectively. Velpatasvir Cmax, AUC and Cmin increased by 55%, 142%, and 301%. Tenofovir Cmax, AUC and Cmin increased by 55%, 30% and 39%, respectively.
Coadministration of tenofovir-DF (300 mg once daily with emtricitabine, darunavir and ritonavir) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 29 subjects. Cmax and AUC of sofosbuvir decreased by 38% and 28%; Cmax, AUC and Cmin of GS-331007 increased by 4%, 13% and 13% respectively. Velpatasvir Cmax and AUC decreased by 24% and 16%, but Cmin increased by 1%. Tenofovir Cmax, AUC and Cmin increased by 55%, 39% and 52%, respectively.
Coadministration of tenofovir-DF (300 mg once daily with emtricitabine and efavirenz) and sofosbuvir/velpatasvir (400/100 mg once daily) increased sofosbuvir Cmax by 38% but decreased AUC by 3%; Cmax and AUC of GS-331007 decreased by 14% and 10%, but Cmin increased by 1%; velpatasvir Cmax, AUC and Cmin decreased by 47%, 53% and 57%, respectively (n=14). Tenofovir Cmax, AUC and Cmin increased by 77%, 81% and 121%, respectively (n=15).
Coadministration of tenofovir-DF (300 mg once daily with elvitegravir/cobicistat/emtricitabine) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 24 subjects. Cmax and AUC of sofosbuvir increased by 1% and 24%; Cmax, AUC and Cmin of GS-331007 increased by 13%, 35% and 45% respectively. Velpatasvir Cmax, AUC and Cmin increased by 5%, 19% and 37%, respectively. Tenofovir Cmax, AUC and Cmin increased by 36%, 35% and 45%, respectively.
Coadministration of tenofovir-DF (300 mg once daily with emtricitabine and rilpivirine) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 24 subjects. Tenofovir Cmax, AUC and Cmin increased by 44%, 40% and 84%, respectively. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed with the combination of emtricitabine, rilpivirine, and tenofovir DF.
Coadministration of tenofovir-DF (300 mg twice daily with emtricitabine and raltegravir) and sofosbuvir/velpatasvir (400/100 mg once daily) increased tenofovir Cmax, AUC and Cmin by 46%, 40% and 70%, respectively (n=30). No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed.
Coadministration of tenofovir-DF (300 once daily with lopinavir, ritonavir and emtricitabine) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 24 subjects. Cmax and AUC of sofosbuvir decreased by 41% and 29%. Cmax, AUC and Cmin of GS-331007 increased by 1%, 15% and 15%, respectively. Velpatasvir Cmax decreased by 30%, but AUC and Cmin increased by 2% and 63%.
No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed with tenofovir DF.
Epclusa US Prescribing Information, Gilead Sciences Inc, June 2016.
No Interaction Expected
Lopinavir/ritonavir (LPV/r)
Sofosbuvir/Velpatasvir
Quality of Evidence: Moderate
Summary:
Based on drug interaction studies conducted with velpatasvir/sofosbuvir, no clinically significant drug interactions have been observed with lopinavir/ritonavir. Coadministration of lopinavir/ritonavir (800/200 mg once daily with emtricitabine and tenofovir-DF, n=24) had no effect on the pharmacokinetic parameters of lopinavir/ritonavir. Cmax and AUC of sofosbuvir decreased by 41% and 29%; velpatasvir Cmax decreased by 30%, but AUC and Cmin increased by 2% and 63%.
Description:
No Interaction Expected
Ritonavir (RTV)
Sofosbuvir/Velpatasvir
Quality of Evidence: Low
Summary:
Coadministration with ritonavir alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although ritonavir is an inhibitor of OATP1B, no clinically significant effect on velpatasvir/sofosbuvir is expected. No significant effects on the pharmacokinetics of ritonavir, sofosbuvir or velpatasvir were observed when velpatasvir/sofosbuvir was coadministered with ritonavir-containing regimens (atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir, all with emtricitabine and tenofovir-DF).
Description:
(See Summary)
No Interaction Expected
Lamivudine (3TC)
Tenofovir-DF (TDF)
Quality of Evidence: Low
Summary:
No significant pharmacokinetic interaction was observed when tenofovir-DF (300 mg once daily) and lamivudine (150 mg twice daily for 7 days) were coadministered. There was no change in AUC, Cmax or Cmin of tenofovir. Lamivudine AUC and Cmin were unaltered, and there was a 24% decrease in Cmax. High rate of virological failure and emergence of resistance reported when lamivudine was combined with tenofovir-DF and abacavir as a once daily regimen.
Description:
There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when lamivudine was combined with tenofovir disoproxil fumarate and abacavir as well as with tenofovir disoproxil fumarate and didanosine as a once daily regimen.
Epivir Summary of Product Characteristics, ViiV Healthcare UK Ltd, February 2019.
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil fumarate was coadministered with lamivudine.
Triple NRTI Therapy:
There have been reports of a high rate of virological failure and of emergence of resistance at early stage when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen.
Viread Summary of Product Characteristics, Gilead Sciences Ltd, September 2016.
Coadministration of tenofovir-DF (300 mg once daily) and lamivudine (150 mg twice daily for 7 days) was studied in 15 HIV-negative subjects. There was no change in tenofovir pharmacokinetic parameters. Lamivudine AUC and Cmin were unaltered, and there was a 24% decrease in Cmax.
Viread Prescribing Information, Gilead Sciences International Inc, February 2016.
No Interaction Expected
Lopinavir/ritonavir (LPV/r)
Lamivudine (3TC)
Quality of Evidence: Very Low
Summary:
No change in the pharmacokinetics of lopinavir was observed when lopinavir/ritonavir was given alone or in combination with stavudine and lamivudine in clinical studies.
Description:
No Interaction Expected
Ritonavir (RTV)
Lamivudine (3TC)
Quality of Evidence: Very Low
Summary:
Lamivudine metabolism does not involve CYP3A, making interactions with protease inhibitors unlikely.
Description:
Lamivudine metabolism does not involve CYP3A, making interactions with medicinal products metabolised by this system (e.g. PIs) unlikely.
Epivir Summary of Product Characteristics, ViiV Healthcare UK Ltd, February 2019.
No Interaction Expected
Lamivudine (3TC)
Sofosbuvir/Velpatasvir
Quality of Evidence: Very Low
Summary:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamivudine is not expected to inhibit or induce any relevant metabolic enzymes or transporters of sofosbuvir/velpatasvir.
Description:
(See Summary)
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.